Abstract
The current NMA results suggest that HLJDD combined with Met is a consistently effective option for reducing both FPG and HbA1c. For HbA1c improvement, while DCHD combined with Met showed initial potential, sensitivity analysis restricted to trials ≥8 weeks identified HLJDD and ZBDHD as the most physiologically robust interventions. However, given the "Very Low" certainty of evidence for many comparisons, these rankings remain exploratory.
Introduction
Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge. While metformin (Met) is established as the first-line pharmacological treatment, many patients experience inadequate long-term glycemic control or intolerable gastrointestinal side effects. In clinical practice, particularly within China, Traditional Chinese Medicine (TCM) classical prescriptions are frequently used as adjunct therapies to enhance metformin's efficacy. However, the evidence supporting these combinations has historically been fragmented, with few head-to-head comparisons between different herbal formulas.
Methods and Study Selection
This study utilized a Bayesian Network Meta-Analysis (NMA) to synthesize evidence from 40 randomized controlled trials (RCTs) involving 3,088 patients. By integrating both direct and indirect evidence, the NMA allowed for the ranking of eight classical TCM formulas when combined with metformin.
The selection process followed rigorous PRISMA guidelines, screening nearly 2,900 records from major international and Chinese databases to identify the final 40 high-quality trials.
Taxonomic Validation and Formula Composition
A critical strength of this analysis was the taxonomic validation of botanical ingredients using the Medicinal Plant Names Services (MPNS). This ensures that the results are based on scientifically identified plant species, addressing a common weakness in herbal medicine research.
The study evaluated eight classical formulas, including Shenling Baizhu powder, Zhibai Dihuang (ZBDHD) decoction, and Huanglian Jiedu (HLJDD) decoction. Each formula consists of a complex mixture of botanical drugs targeting different aspects of T2DM pathophysiology.
Key Findings
The NMA provided a hierarchy of treatment efficacy using Surface Under the Cumulative Ranking (SUCRA) curves:
- Glycemic Control: Huanglian Jiedu Decoction (HLJDD) combined with metformin emerged as the most effective for reducing Fasting Plasma Glucose (FPG).
- Long-term Robustness: While Dachaihu Decoction (DCHD) initially appeared effective for HbA1c, sensitivity analysis restricted to trials of 8 weeks or longer identified HLJDD and Zhibai Dihuang Decoction (ZBDHD) as the most robust options for stable glycemic control.
- Metabolic Markers: Huanglian Wendan Decoction (HLWDD) showed significant potential in improving lipid profiles, specifically total cholesterol and LDL-c.
Safety and Evidence Quality
Despite the promising efficacy results, the study highlights a significant gap in safety reporting. Only 20% of the included trials provided safety data. While no severe adverse events were reported, the lack of standardized reporting prevents a definitive safety profile. Furthermore, the GRADE assessment categorized the certainty of evidence as "Very Low," primarily due to the high risk of bias (lack of blinding) and small sample sizes in the original trials.
Conclusion
HLJDD and ZBDHD combined with metformin represent promising therapeutic strategies for T2DM. However, the "Very Low" certainty of the current evidence base necessitates caution. Future research should focus on large-scale, multi-center, double-blind RCTs with standardized safety reporting and direct head-to-head comparisons between herbal formulas to provide more definitive clinical guidance.
Summary updated